Showing results (421-430 of 455) with videos related to

Sort By:
Pageof 46
Nature Plants|June 12, 2019
Sphingolipid biosynthesis modulates plasmodesmal ultrastructure and phloem unloadingDawei Yan, Shri Ram Yadav, Andrea Paterlini, et al.
Nature Plants|August 18, 2019
Publisher Correction: Sphingolipid biosynthesis modulates plasmodesmal ultrastructure and phloem unloadingDawei Yan, Shri Ram Yadav, Andrea Paterlini, et al.
Acta Dermato-Venereologica|March 19, 2015
Sentinel node status and immunosuppression: recurrence factors in localized Merkel cell carcinomaThomas Jouary, Emeline Kubica, Stéphane Dalle, et al.
Cancer|December 8, 2024
Methods of nivolumab administration in advanced melanoma: A comparison of patients' clinical outcomes treated with flat dose or weight-adjusted dose, a multicenter observational studyIona Campo Le Brun, Séphane Dalle, Laurent Mortier, et al.
Human Molecular Genetics|March 17, 2012
Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in humanNathalie Roux-Buisson, Marine Cacheux, Anne Fourest-Lieuvin, et al.
Journal of Medical Genetics|September 30, 2020
Clinical phenotype and loss of the slow skeletal muscle troponin T in three new patients with recessive TNNT1 nemaline myopathyJustine Géraud, Klaus Dieterich, John Rendu, et al.
Clinics and Research in Hepatology and Gastroenterology|December 14, 2024
Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD studyVictoire Dabout, Laurent Mineur, David Tougeron, et al.
EMBO Reports|July 10, 2019
Multiple C2 domains and transmembrane region proteins (MCTPs) tether membranes at plasmodesmataMarie L Brault, Jules D Petit, Françoise Immel, et al.
Breast Cancer (Tokyo, Japan)|January 5, 2023
CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patientsCaroline Bailleux, Antoine Arnaud, Jean-Sébastien Frenel, et al.
Annals of the Rheumatic Diseases|July 5, 2022
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control studyLéo Plaçais, Stéphane Dalle, Olivier Dereure, et al.
Pageof 46